Welcome to our dedicated page for Ultragenyx Pharmaceutical SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ultragenyx Pharmaceutical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ultragenyx Pharmaceutical's regulatory disclosures and financial reporting.
RARE affiliate disclosed proposed and recent resales of Common Stock on a Form 144. The filing lists scheduled issuances of Restricted Stock and Performance Shares with grant dates and quantities, and records two recent open-market sales by Howard Horn of 4,653 shares on 06/01/2026 for $110,601.81 and 4,683 shares on 05/01/2026 for $116,606.70.
Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. sold 2,000 shares of Common Stock in an open-market transaction at $25.05 per share. After this sale, the director directly holds 21,095 shares. The reported holdings include previously disclosed RSUs that will vest over time.
Ultragenyx Pharmaceutical Inc. executive Karah Herdman Parschauer reported an open-market sale of 1,899 shares of common stock at $24.62 per share. After this transaction, she directly holds 94,462 shares. Her holdings include 646 shares acquired under the company’s Employee Stock Purchase Plan and previously reported RSU-based common stock that remains subject to vesting conditions.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice reporting proposed dispositions of Common Stock on 06/15/2026 for shares tied to prior restricted stock grants. The filing lists 1,298 shares from a 06/29/2022 restricted stock award and 702 shares from a 06/07/2023 restricted stock award; total listed in the excerpt is 2,000 shares.
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of common stock. On June 1, 2026, he sold 4,653 shares at a price of $23.77 per share. After this transaction, he directly holds 105,689 shares, which include previously reported shares underlying RSUs that remain subject to vesting conditions.
Howard Horn reported proposed sales of Common Stock on Form 144. The filing lists multiple proposed dispositions by Howard Horn with transaction dates in 2026 and earlier, including individual sales of 4,683 shares for $116,606.70 on 05/01/2026 and 4,683 shares for $98,202.51 on 04/01/2026. The entries identify the securities as Performance and Restricted Stock and list Morgan Stanley Smith Barney LLC as the broker.
Ultragenyx Pharmaceutical Inc. director Matthew K. Fust reported receiving equity compensation in the form of both restricted stock units and stock options. He was granted 7,751 shares of Common Stock as Restricted Stock Units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 33,696 shares following the award.
He was also granted a stock option for 14,058 shares of Common Stock with an exercise price of $25.80 per share, representing his full reported option position after this grant. Both the RSUs and the stock option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.
Ultragenyx Pharmaceutical Inc. director Shehnaaz Suliman reported a mix of equity awards and a share sale. On May 14, 2026, she received 7,751 Restricted Stock Units under the company’s 2023 Incentive Plan and a stock option for 14,058 shares with a $25.80 exercise price, both vesting in full on the earlier of the next Annual Meeting of Stockholders or May 14, 2027. On May 18, 2026, she executed an open-market sale of 5,740 shares of common stock at $25.12 per share, leaving her with 27,951 common shares held directly after the sale.
Ultragenyx Pharmaceutical Inc. director Ray Amrit reported new equity awards consisting of both restricted stock units and stock options. He received 7,751 shares of Common Stock as Restricted Stock Units granted under the Company’s 2023 Incentive Plan. After this award, he directly holds 31,116 shares of Common Stock.
Amrit was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the Company’s next Annual Meeting of Stockholders or May 14, 2027, making this a routine, compensation-related acquisition rather than an open-market purchase.